Amgen – Raymond James Maintains a Maintain Ranking on Amgen (AMGN)
Raymond James analyst Dane Leone maintained a Maintain ranking on Amgen (AMGN) at present. The corporate’s shares closed final Friday at $253.50, near its 52-week excessive of $264.97.
In accordance with TipRanks.com, Leone is a 5-star analyst with a mean return of 18.1% and a 65.6% success price. Leone covers the Healthcare sector, specializing in stocks resembling Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Prescription drugs.
The phrase on The Street usually, suggests a Average Purchase analyst consensus ranking for Amgen with a $268.44 common price goal, which is a 6.4% upside from present ranges. In a report issued on January 11, J.P. Morgan additionally maintained a Maintain ranking on the stock.
See at present’s analyst prime beneficial stocks >>
Based mostly on Amgen’s newest earnings launch for the quarter ending September 30, the corporate reported a quarterly income of $6.42 billion and internet revenue of $2.02 billion. Compared, final 12 months the corporate earned income of $5.74 billion and had a internet revenue of $1.97 billion.
TipRanks has tracked 36,000 firm insiders and located that just a few of them are higher than others on the subject of timing their transactions. See which 3 stocks are almost certainly to make strikes following their insider actions.
Amgen, Inc. is a biotechnology firm, which engages within the discovery, improvement, manufacture and advertising and marketing of human therapeutics. Its merchandise embody the next manufacturers: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The corporate was based by William Ok. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.